AU2023219516A1 - 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same - Google Patents

2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same Download PDF

Info

Publication number
AU2023219516A1
AU2023219516A1 AU2023219516A AU2023219516A AU2023219516A1 AU 2023219516 A1 AU2023219516 A1 AU 2023219516A1 AU 2023219516 A AU2023219516 A AU 2023219516A AU 2023219516 A AU2023219516 A AU 2023219516A AU 2023219516 A1 AU2023219516 A1 AU 2023219516A1
Authority
AU
Australia
Prior art keywords
groups
alkyl
optionally substituted
compound
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023219516A
Other languages
English (en)
Inventor
Leslie A. DAKIN
Elena DOLGIKH
Jessica H. OLSEN
Timothy J. SENTER
Akira J. SHIMIZU
Steven D. STONE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2023219516A1 publication Critical patent/AU2023219516A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2023219516A 2022-02-08 2023-02-08 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same Pending AU2023219516A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263307933P 2022-02-08 2022-02-08
US63/307,933 2022-02-08
PCT/US2023/012579 WO2023154310A1 (en) 2022-02-08 2023-02-08 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
AU2023219516A1 true AU2023219516A1 (en) 2024-08-22

Family

ID=85570218

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023219516A Pending AU2023219516A1 (en) 2022-02-08 2023-02-08 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same

Country Status (7)

Country Link
US (1) US20250163021A1 (https=)
EP (1) EP4476199A1 (https=)
JP (1) JP2025505200A (https=)
CN (1) CN118984821A (https=)
AU (1) AU2023219516A1 (https=)
CA (1) CA3251230A1 (https=)
WO (1) WO2023154310A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) * 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US6518423B1 (en) * 1996-08-09 2003-02-11 Eisai Co., Ltd. Benzopiperidine derivatives
AR048523A1 (es) * 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
JP5406722B2 (ja) * 2006-10-16 2014-02-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ブラジキニン１受容体モジュレータとしての置換されたスルホンアミド誘導体
BR102012024778A2 (pt) * 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
CN106749330A (zh) * 2016-12-29 2017-05-31 长春海谱润斯科技有限公司 一种杂环衍生物及使用该杂环衍生物的有机发光器件
US20220144838A1 (en) * 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
IL296423A (en) * 2020-04-22 2022-11-01 Anima Biotech Inc Collagen 1 translation inhibitors and methods of use thereof
CN115867532A (zh) * 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1的抑制剂及其用途

Also Published As

Publication number Publication date
JP2025505200A (ja) 2025-02-21
CA3251230A1 (en) 2023-08-17
US20250163021A1 (en) 2025-05-22
EP4476199A1 (en) 2024-12-18
CN118984821A (zh) 2024-11-19
WO2023154310A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
AU2023219516A1 (en) 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
US12116343B2 (en) Inhibitors of APOL1 and methods of using same
CN110352188B (zh) 氟代烯丙胺衍生物及其用途
EP2917210B1 (en) Alk kinase inhibitors
US12612379B2 (en) Inhibitors of APOL1 and methods of using same
PH12014502573B1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
WO2023101981A1 (en) Spirocyclic inhibitors of apol1 and methods of using same
KR20170125897A (ko) 플루오르화된 리실 옥시다아제-유사 2 억제제 및 이의 용도
WO2003055866A1 (en) Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2023154309A1 (en) 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
EP4126863A1 (en) 1 h-pyrazolo[4,3-g]isoquinoline and 1 h-pyrazolo[4,3-g]quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
CN113773335A (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
EP3105232B1 (en) Substituted triazolobenzodiazepines
WO2007008142A1 (en) Heterocyclic sulfonamide derivatives as inhibitors of factor xa
EP4182322B1 (en) Pyrido oxazine derivatives as alk5 inhibitors
CN105878243A (zh) 吡非尼酮衍生物在制药中的应用
HK1210169B (en) Triazolopyrazine
TW201307321A (zh) 新苯甲基羥吲哚嘧啶